Project 3: Epidemiological and Clinical Translational Studies Post Genome-Wide Association (GWAS) Project Leader: Rosalind Eeles Project Summary: The main focus of Project 3 is establishing a transdisciplinary collaborative network comprised of clinical scientists, epidemiologists, geneticists, and biostatisticians focusing on the transition from 'bench-side'research to 'bed-side'care. The CEC (Clinical ELLIPSE Consortium) will harmonize genetic, clinical, and environmental data from existing consortia, with over 35,000 prostate cancer cases, to evaluate gene, genegene, and gene-environmental effects on prostate cancer risk, including aggressive disease, recurrence, and mortality. The highly integrated ELLIPSE projects will facilitate the most up to date genetic evaluation by working closely with Project 1, identifying novel genetic candidates, and Project 2, providing biological insights on function. The assessment of genetic and environmental interactions will be evaluated for inclusion into a risk score as well as potentially providing directional input for Projects 1 and 2. All risk evaluations will be assessed in European, African American, and Japanese populations. Finally, this initial stage will provide the necessary guidance in developing useful and powerful risk prediction models for prostate cancer risk, including screening, outcome and treatment effects. These risk prediction models may have an immediate public health impact by providing clinicians with the necessary tools to improve clinical-decision making.

Public Health Relevance

The main focus of this project is to establish a transdisciplinary network of highly innovative scientists investigating the impact of genetic, environmental, and effect modifiers (ie gene-gene and gene-environment) on prostate cancer risk in a multiethnic sample. In particular, this project will initiate the process the of going from the 'bench-side'to the 'bed-side'by developing risk prediction models needed in prostate cancer prediction, screening, progression, and treatments.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-4)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Southern California
Los Angeles
United States
Zip Code
Lindström, Sara; Finucane, Hilary; Bulik-Sullivan, Brendan et al. (2017) Quantifying the Genetic Correlation between Multiple Cancer Types. Cancer Epidemiol Biomarkers Prev 26:1427-1435
Park, Sungshim L; Cheng, Iona; Haiman, Christopher A (2017) Genome-wide association studies of cancer in diverse populations. Cancer Epidemiol Biomarkers Prev :
Glubb, Dylan M; Johnatty, Sharon E; Quinn, Michael C J et al. (2017) Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget 8:64670-64684
Amos, Christopher I; Dennis, Joe; Wang, Zhaoming et al. (2017) The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. Cancer Epidemiol Biomarkers Prev 26:126-135
Sud, Amit; Thomsen, Hauke; Law, Philip J et al. (2017) Genome-wide association study of classical Hodgkin lymphoma identifies key regulators of disease susceptibility. Nat Commun 8:1892
Feng, Yen-Chen Anne; Cho, Kelly; Lindstrom, Sara et al. (2017) Investigating the genetic relationship between Alzheimer's disease and cancer using GWAS summary statistics. Hum Genet 136:1341-1351
Zuber, Verena; Bettella, Francesco; Witoelar, Aree et al. (2017) Bromodomain protein 4 discriminates tissue-specific super-enhancers containing disease-specific susceptibility loci in prostate and breast cancer. BMC Genomics 18:270
Milne, Roger L (see original citation for additional authors) (2017) Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nat Genet 49:1767-1778
Shimelis, Hermela; Mesman, Romy L S; Von Nicolai, Catharina et al. (2017) BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Res 77:2789-2799
Muranen, Taru A; Greco, Dario; Blomqvist, Carl et al. (2017) Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genet Med 19:599-603

Showing the most recent 10 out of 131 publications